Federation Bio was co-founded by Stanford and Venrock in 2019. Based on the work of two professors at Stanford – Dr. Michael Fischbach and Dr. Dylan Dodd – Federation Bio is pioneering powerful synthetic microbial cell therapies that have demonstrated potential to treat a wide range of diseases – from metabolic disorders to metastatic cancers. Unlike earlier approaches to microbial therapeutics, Federation Bio is generating potent, reproducible, and complete microbial consortia that stably engraft to provide predictable and durable responses.
Foundational to the company’s scientific approach is its first-in-class ACT™ (anaerobic co-culture technology) platform, which allows rapid and scalable manufacturing of rationally designed complex bacterial consortia.
Learn how we are applying bold scientific advancements to champion the needs of patients.
Lee Swem, Ph.D.Chief Scientific Officer
Andreas Grauer, M.D.Chief Medical Officer
Jessie Richardson, J.D., Ph.D.Chief Legal Officer
Joumana Zeid, MS, MBAVice President, Project Team Leadership and Portfolio Strategy
Kyle Jacoby, Ph.D.Vice President, Research
Marguerite Prior, Ph.D.Senior Director, Regulatory Affairs
Board of Directors
Racquel BrackenCo-founder, Federation Bio
Emily Drabant Conley, Ph.D.CEO, Federation Bio
Michael Fischbach, Ph.D.Co-founder, Federation Bio
Associate Professor of Bioengineering, Stanford
Bryan Roberts, Ph.D.Partner, Venrock
John Stuelpnagel, D.V.M., MBACo-founder and former CEO of Illumina
Chairman of 10X Genomics, Ariosa & Inscripta